Patent ID: 7064148

Claim:
A method for treating disease by opening ClC channels in a mammalian subject, wherein the disease is selected from the group consisting of myotonia atrophica, calculus renum, constipation, anxiety, insomnia, epilepsia, anesthesia, asthma, bronchitis and neuropathy, which comprises administering an effective amount of a prostaglandin compound to the subject, wherein said prostaglandin compound is the compound as shown by the following general formula (I): wherein L, M and N are hydrogen atom, hydroxy, halogen atom, lower alkyl, hydroxy(lower)alkyl, or oxo, wherein at least one of L and M is a group other than hydrogen, and the five-membered ring of formula (I) may have one or more double bonds; A is —CH 2 OH, —COCH 2 OH, —COOH or a pharmaceutically acceptable salt, ether, ester or amide thereof; B is —CH 2 —CH 2 —, —CH═CH— or —C≡C—; Zis wherein R 4 and R 5 are hydrogen, hydroxy, halogen, lower alkyl, lower alkoxy or hydroxy(lower)alkyl, wherein R 4 and R 5 are not hydroxy and lower alkoxy at the same time; R 1 is a saturated or unsaturated bivalent lower or medium aliphatic hydrocarbon residue, which is unsubstituted or substituted with halogen, alkyl, hydroxy, oxo, or aryl, and at least one carbon atom in the aliphatic hydrocarbon is optionally substituted by oxygen, nitrogen or sulfur; and Ra is a saturated or unsaturated lower or medium aliphatic hydrocarbon residue, which is unsubstituted or substituted with halogen, oxo, hydroxy, lower alkoxy, lower alkanoyloxy, cyclo(lower)alkyl, cyclo(lower)alkyloxy, aryl, or aryloxy; cyclo(lower)alkyl; cyclo(lower)alkyloxy; aryl; or aryloxy.